Evidence map›Paper›PMID 27220667›Full record

ArticleLeukemia2016

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.

H Wu, A Wang, Z Qi, X Li, C Chen, K Yu, F Zou, C Hu, W Wang, Z Zhao and 17 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. [Advancesin FLT3 inhibitors for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
    Article
  5. Article
  6. [Advances in targeted therapy for childhood acute myeloid leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 2 countries.

H WuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
A WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Z QiHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
X LiHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
C ChenHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
K YuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
F ZouHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
C HuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
W WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Z ZhaoHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
J WuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
J LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
X LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
L WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
W WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
S ZhangCHMFL-HCMTC Target Therapy Joint Laboratory, Hefei, China.
R M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
I A GalinskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
J D GriffinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
D WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
A ChristodoulouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
H WangDepartment of Hematology, The Second Hospital of Anhui Medical University, Hefei, China.
Y ShenDepartment of Hematology, The Second Hospital of Anhui Medical University, Hefei, China.
Z ZhaiDepartment of Hematology, The Second Hospital of Anhui Medical University, Hefei, China.
E L WeisbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
J LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Q LiuHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
High Magnetic Field Laboratory · CNUniversity of Science and Technology of China · CNAnhui Medical University · CNChinese Academy of Sciences · CNDana-Farber Cancer Institute · USHarvard University · USHefei University of Technology · CN

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI JEROME RITZ · 1996 to 2026
$52.5M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6M
NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DiscoveryAnimalsCell Line, TumorHumansLeukemia, Myeloid, AcuteMiceProtein Kinase InhibitorsProtein Kinase Inhibitors

Identifiers

PMID27220667
PMCPMC5053879
OpenAlexW2401421100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.